Course overview

The GI Microbiome and Autoimmunity

This course will review autoimmune disorders, their relationship to the microbiome, labs for autoimmune disease assesseent including qPRC molecular methods of assessing GI microbiota, as well as emerging predictive antibody testing.
 Faculty

David Brady, ND, DC,CCN, DACBN, IFMCP, FACN

 Conference Series

AIHM 2019 Annual Conference

 Required Lessons

1

 Time to Complete

1 hour

 Non-CME Eligible*

0 Credits

What you will learn

  • Course Summary

  • Autoimmune disease is growing at epidemic proportions. Standard interventions are based on symptom control and immune suppression. This presentation with review a proactive integrative, systems biology, approach for the provider to address disease prediction, prevention and treatment, including various evidence-based modalities. The role of the GI microbiota will be emphasized, along with food immune reactions, stealth infections and molecular mimicry in autoimmune disease pathogenesis will be explored along with how these may serve as leverage points for clinical interventions. The hygiene hypothesis and changes in early environmental antigen exposure will also be explored. New opportunities for proactive screening for at-risk subjects for autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel diseases, diabetes, multiple sclerosis, lupus, and others using qPCR molecular methods of assessing the GI microbiota, as well as emerging predictive antibody testing, will also be reviewed and discussed from the perspective of the natural and integrative practitioner.
    By the end of this course, learners will be able to:

    • Identify the linkage and association between autoimmune disease prevalence and factors including the GI microbiota composition, food immune reactions, stealth infections, molecular mimicry, lack of early diverse antigen exposure, and other elements.
    • Recognize the available clinical laboratory testing related to autoimmune disease risk assessment, diagnosis, and clinical management, including qPCR molecular-based evaluation of the GI microbiota, various food sensitivity assays, and predictive autoantibody tests.
    • Explain the difference between quantitative molecular testing (qPCR) versus next-generation sequencing of the GI microbiota in the support of clinical decision making.
    • Identify the available evidence-based integrative and complementary therapeutic interventions for autoimmune disorders.
    • Utilize strategies of collaborative care for patients with autoimmune disorders.

Course includes:

  • Video recording
  • Downloadable audio
  • Speaker handout(s)
  • 1 Quiz
  • 1 Evaluation
  • Certificate of Completion

Included in this course

Course Faculty

David Brady, ND, DC,CCN, DACBN, IFMCP, FACN

Faculty Disclosures: Employer - Designs for Health, Inc. & Diagnostic Solutions Labs, LLC; Major Stock Shareholder/Board Member - Diagnostic Solutions, Labs, LLC
About David
Dr. Brady has 28 years of experience as an integrative practitioner and over 24 years in health sciences academia. He is a licensed naturopathic medical physician in Connecticut and Vermont, is board certified in functional medicine and clinical nutrition a a fellow of the American College of Nutrition, and completed his initial clinical training as a doctor of chiropractic. Dr. Brady is the chief medical officer of Designs for Health, Inc. and Diagnostic Solutions Labs. He is the long-time director of the Human Nutrition Institute, at the University of Bridgeport in Connecticut. He has appeared on the plenary speaking panel of IFM, ACAM, A4M, ACN, IHS, AANP and many more. He is in clinical practice at Whole Body Medicine in Fairfield, CT.

*CME/CEU Credits

The CME for this course has expired, however you will continue to have access to your purchased content. 

Enroll Now!

This course is self-paced with no set beginning or end date. You may complete this course on your own schedule and pace. Enrolling in and purchasing this course grants you access to its contents in perpetuity.